Skip to content

4D Pharma Shares Rally On Positive Asthma Treatment Trial Results

Sam Boughedda trader
Updated 13 Dec 2021

4D Pharma (LON: DDDD) shares have rallied Monday morning on the back of positive data from the Part A of phase 1/2 clinical trial of the company's asthma treatment, MRx-4DP0004.

The Phase 1/2 trial is a study in patients with partly controlled asthma taking long-term medication. 

The primary endpoint of Part A, which was to evaluate the safety and tolerability of MRX-4DP0004, was met. The secondary endpoints were evaluating clinical activity, with 4D saying “multiple key secondary endpoints” were achieved. 

The company told investors that MRx-4DP0004 generated promising signals of clinical activity, which supports progression into Part B of the study, which is expected to enroll up to 90 patients.

“The results from Part A of 4D pharma's Phase I/II study of MRx-4DP0004 as a treatment for asthma are an important step forward in our development of a new safe oral therapeutic for asthma patients,” said Dr. Alex Stevenson, Chief Scientific Officer of 4D pharma. 

“Not only do the results support the excellent safety profile shown to date across our clinical pipeline of Live Biotherapeutics for a variety of indications, but also demonstrate our ability to identify and develop single strain LBPs with potent systemic activity using our MicroRx platform,” he added.

4D Pharma shares hit a high of 64.7p in early Monday trading. Last week, in a similar move, 4D Pharma shares jumped to a high of  67.2p before retracing after it reported positive data regarding its clinical trial of Blautix, a medicine for irritable bowel syndrome. 

Should you invest in 4D Pharma shares?

4D Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are DDDD shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.